News|Articles|August 16, 2023

CPHI to Return to Milan in 2024

Author(s)Grant Playter

CPHI 2024 will return to the Fiera Milano in Milan, Italy.

CPHI, a pharmaceutical conference covering everything in the pharma spectrum from ingredients to packaging, announced on August 15, 2023 that it would be returning to Milan, Italy in 2024. The global pharma exhibition will be hosted at the Fiera Milano from October 8-10, 2024.

According to a press release from Informa, the event organizers, the 2024 event is expected to see record attendance due to a large number of international visitors and a rapid increase in attendees from major Asian pharma hubs. The event was previously held at this location for CPHI 2022.

“We are delighted to be returning to Fiera Milano, as Italy and the Lombardy region are widely known as one of the key pharma manufacturing centers in Europe,” said Adam Anderson, executive vice-president, Pharma, at Informa. “There are very few global locations with such a depth and breadth of local and regional talent. We expect a large international attendance and will marry this with local and regional manufacturing insights. I am excited to bring CPHI … back together with the industry in Milan.”

“Fiera Milano is the ideal venue for a global event like CPHI, which is an important tenet of this industry and central to the world economy, with the Lombardy region being a leading producer of pharmaceuticals,” said Roberto Foresti, deputy general manager of Fiera Milano, in the release. “What makes Milan so attractive is that the city has world-class infrastructure and is well connected to European, Asian, and North American countries. It’s why Fiera Milano continues to attract massive international events.”

Source: Informa


Related to this article

The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.